⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480956 | 1.00 | — | — | |
| SCHEMBL30014401 | 0.81 | — | — | |
| SCHEMBL2088616 | 0.81 | — | — | |
| SCHEMBL4152897 | 0.79 | — | — | |
| SCHEMBL30197278 | 0.79 | — | — | |
| SCHEMBL13351204 | 0.79 | — | — | |
| SCHEMBL18624696 | 0.75 | — | — | |
| SCHEMBL10076714 | 0.75 | — | — | |
| SCHEMBL6644336 | 0.75 | — | — | |
| SCHEMBL22182564 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023230026-A1 | PIPERIDINYL-METHYLPURINE BENZENES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| WO-1997044337-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| US-5250527-A | Enzyme inhibitors; administering to reduce gastric acid secretion | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-10-05 | — | — | US | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| CN-1013445-B | PROCESS FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS | SMITH KLINE FRENCH LAB (GB) | 1991-08-07 | — | — | CN | disclosed |
| EP-0184322-B1 | BENZIMIDAZOLES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| EP-0184322-A1 | Benzimidazoles | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-06-11 | — | — | EP | disclosed |
| CN-85108133-A | Compounds process for production thereof | — | 1986-04-10 | — | — | CN | disclosed |